Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI Palantir Fixed Tech100 Index (KPLTT100)
5/21/2026, 12:00:00 AM
Announced positive results from the Phase 1/2 LINKER-AL2 trial for Lynozyfic (linvoseltamab) in patients with systemic amyloid light chain (AL) amyloidosis.
Korean Translation
전신성 아밀로이드 경쇄(AL) 아밀로이드증 환자를 대상으로 한 Lynozyfic(linvoseltamab)의 1/2상 LINKER-AL2 임상시험에서 긍정적인 결과를 발표함.
Related Recent Events
Apple Inc (AAPL) · Other
CEO Tim Cook is scheduled to transition to the role of Executive Chair, with John Ternus, current SVP of Hardware Engineering, becoming the new CEO on September 1, 2026, which analysts forecast will result in a ~5% price impact, scheduled.
9/1/2026, 12:00:00 AM
Cisco Systems Inc (CSCO) · Earnings Release
Cisco's Q4 FY2026 earnings release is scheduled for August 12, 2026, based on past reporting schedules; high volatility is expected.
8/12/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
AMD Q2 2026 earnings release and $11.2B revenue guidance (46% YoY growth); medium importance justified by estimated >=5% price impact scheduled.
8/4/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is scheduled for July 30, 2026, where analysts forecast an EPS of approximately $1.81-$1.82. Medium importance is estimated as earnings releases typically trigger 5-10% price volatility forecasted.
7/30/2026, 12:00:00 AM
Comcast Corp (CMCSA) · Earnings Release
Comcast is scheduled to release its Q2 2026 earnings results on 2026-07-30. Analysts forecast earnings of approximately $0.99 per share. A price impact of ≥5% is estimated based on historical earnings volatility, scheduled.
7/30/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 financial results on July 30, 2026; a 1-5% impact is estimated as the market anticipates the report, scheduled.
7/30/2026, 12:00:00 AM